Elephas Bioscience to Present New Functional Precision Medicine Data at SITC 2026

New Ex Vivo Data, Symposium with Netherlands Cancer Institute and AstraZeneca, and elive™ Edge Demonstrations at 41st Annual Meeting

MADISON, Wis., October 1st, 2026 - Elephas Biosciences Corporation, developer of the elive™ functional precision medicine platform, today announced its participation in the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, November 4-8 in Phoenix, Arizona. Committed to improving the lives of those affected by cancer, Elephas will showcase its growing body of research in functional precision medicine through a poster presentation featuring new data, a scientific symposium featuring speakers from Netherlands Cancer Institute and AstraZeneca, and live demonstrations of its elive™ Edge tissue cutting instrument.

"SITC brings together some of the leading minds in immunotherapy, making it an important forum to advance the conversation around functional precision medicine and human-relevant models," said Hinco Gierman, PhD, Chief Scientific Officer at Elephas. "We're excited to share new data, welcome our esteemed symposium speakers, and show how the elive platform can support both clinical research and drug development."

Where to find Elephas at SITC:

Poster Presentation:

● Date: Friday November 6, 12:00-2:00 p.m. and 5:00-7:00 p.m.

● Title: Characterization of immune phenotypes associated with ex vivo response to immune checkpoint inhibitors in live tumor fragments from core needle biopsies

● Presenter: Christin Johnson

Symposium:

● Date: Saturday, November 7, 12:30-1:30p.m.

● Title: Platforms for ex vivo profiling of patient-derived live tumor fragments accurately predict response to ICI and can be used to evaluate mechanisms of action and resistance

● Featured Speakers:

• Daniela Thommen, MD, PhD - Associate Professor at Netherlands Cancer Institute and pioneer in ex vivo cytokine profiling to predict patient response

• Jeremy Ratiu, PhD - Associate Principal Scientist at AstraZeneca, on dissecting the mechanism of action of bispecific antibody rilvegostomig ex vivo

• Hinco Gierman, PhD - Chief Scientific Officer, Elephas, on measuring and predicting response to immunotherapy for drug development and diagnostics with small routine biopsies

Booth Presence: Attendees can visit Elephas at booth #1035 for demonstrations of the elive™ Edge instrument and see how our proprietary instrument can cut human tumor tissue into

precise fragments. Edge technology is ideal for both scientific research and clinical development. Attendees can stop by the Elephas booth during exhibit hall hours and connect with members of the Science, Medical and Product teams for in-depth conversations about the elive platform and its use in accelerating functional precision medicine.

To learn more about our attendance, get in touch or register for the symposium, please visit: https://landing.elephas.com/sitc-2026.

About Elephas Biosciences

Elephas is a global leader in functional precision medicine. Our elive platform is a breakthrough live-tissue technology designed to measure therapeutic response across oncology treatment.

Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies and targeted therapies, only a fraction of patients receiving these treatments obtain a response, and many who may respond are not eligible for therapy due to a lack of accurate predictive biomarkers.

With the mission to tackle this growing dilemma, Elephas has developed an ex vivo platform to assess how live tumor tissue responds to oncology therapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive platform provides a functional readout, offering valuable insights. To learn more, visit www.elephas.com and follow us on LinkedIn.

Elephas Media Contact

John Fitzpatrick

[email protected]

Elephas Investor Contact

Ji-Yon Yi

[email protected]